Avacta signs license agreement with Astrea Bioseparations
Industry News: Avacta signs license agreement with Astrea Bioseparations
30 Dec 2020
Avacta Group, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer
® and pre|CISION™ platforms, has announced that it has entered into a license agreement with Astrea Bioseparations (“Astrea”) for the use of the Affimer platform in affinity purification applications.
Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences, the life sciences tools platform created by KKR, to build a leading position in next-generation bioprocessing for advanced therapies.
Published: Dec 24, 2020 By Alex Keown
The European Union (EU) authorized
ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in conjunction with Janssen’s Edurant (rilpivirine tablets) for the treatment of HIV-1 infection in adults who are virologically suppressed. Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. The approval of ViiV’s treatment is the first time HIV-1 patients in Europe may be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets, following the oral initiation phase.
Avacta Group agreement with Astrea Bioseparations ‘the perfect deal’ (Interview) 7:29 am
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss the agreement with Astrea Bioseparations. Alastair explains what affinity separation is, tell us about the market, the details of the deal, how it fits in with the company strategy, other opportunities and progress with the SARS-CoV-2 rapid antigen test.
Avacta Group is developing novel cancer immunotherapies combining its two proprietary platforms – Affimer® biotherapeutics and pre|CISIONTM tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company’s therapeutics development activities are based in Cambridge, UK.
Avacta Group license agreement with Astrea Bioseparations for affinity purification applications 7:13 am
Avacta Group plc (LON:AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer
® and pre|CISION
TM platforms, has announced that it has entered into a license agreement with Astrea Bioseparations for the use of the Affimer platform in affinity purification applications.
Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences, the life sciences tools platform created by KKR, to build a leading position in next-generation bioprocessing for advanced therapies.
Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology
News provided by
Share this article
Share this article
MENLO PARK, Calif. and CAMBRIDGE, United Kingdom, Dec. 21, 2020 /PRNewswire/ Gamma Biosciences, a life sciences tools platform created by KKR, today announced a licensing agreement between Astrea Bioseparations, a leader in affinity chromatography and bioseparations, and Avacta, a developer of innovative cancer therapies and diagnostics based on proprietary Affimer® and preCISION™ platforms. The licensing agreement gives Astrea access to the Affimer technology for applications in bioprocessing, expanding its range of ligand discovery and development capabilities to include best-in-class chemical and biological platforms for customer development programs.